Leading Scientists to Present Computational and Informatics Solutions at Accelrys Science Forum Series
News Oct 10, 2007
Innovative science and technology will be the focus of a major seminar series by Accelrys, Inc., a provider of scientific modeling and workflow software solutions.
The seminar series us expected to provide a look at the most recent developments in modeling and simulation, informatics and data integration analysis and reporting and will feature presentations by scientists from industry, academia and Accelrys. The event is free for registrants and will be held at locations throughout the US and Europe.
Science Forum dates and locations in the US include: October 23: Boston, Massachusetts, October 25: Princeton, New Jersey, October 30: San Diego, CA, November 13: Houston, Texas, (Note: Chemicals/Materials only) November 15: San Francisco, California.
The seminar features tracks for Pharmaceutical and Biotechnology Research, Chemicals and Materials R&D, and Platform, Informatics, and Reporting. Topics in the Pharmaceutical and Biotechnology track include rational flexible docking, QM/MM, pk predictions for proteins, antibody modeling and docking, and de novo fragment-based design.
In the Chemicals/Materials track topics include catalysis, nanotechnology, crystallization, and QSAR. Topics in the Platform and Informatics track include enterprise and desktop cheminformatics solutions, reporting and drill-down dashboards, high content analysis, and web service & application development within an SOA environment.
Accelrys customers and potential customers will also have the opportunity to see and use recent Accelrys product releases including Discovery Studio 2.0, Materials Studio 4.2 and Pipeline Pilot 6.1 as part of the hands-on workshop included in the forum.
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE